A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

Clinical trial NCT06031584 · RECRUITING

Trial details

NCT number: NCT06031584
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Her2-positive/Low-expression Urinary and Digestive Tract Tumors

Start date: 2024-01-19
Primary completion: 2026-12-01
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.